Did You Know?

Editor’s Picks

Latest News

Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development

ALG-097558 demonstrates nanomolar potent antiviral activity and is up to 20-fold more active than nirmatrelvir in cell-based assays against multiple...

CymaBay Therapeutics Announces Publication of Results From a 52-Week, Open-Label, Phase 2 Study of Seladelpar in Patients With Primary Biliary Cholangitis

NEWARK, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and...

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual Meeting

Patient Safety Movement Foundation Announces Dates and Speaker Line-up for 8th Annual World Patient Safety, Science & Technology Summit

Event Brings Together Key Industry Leaders and Healthcare Organizations to Confront Leading Patient Safety Issues IRVINE, Calif.--(BUSINESS WIRE)--#0X2030--The Patient Safety...

Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for Anti-CD112R Monoclonal Antibody for Treatment of Advanced Solid Tumors

SHANGHAI, China, April 03, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a...

Sotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22)

Late-breaking presentation of analysis of SCORED clinical trial data describes significant reduction in cardiovascular death, myocardial infarction and stroke with...

error: Content is protected !!